Potency was defined as an IIEF-5>17. In both the continuous and categorical analyses, patients showed a higher rate of sexual function recovery at 3 and 12 months: 17.35% RH patients returned to potency by 3 months, as compared to 9.7% in the control group (p<0.001). The difference in recovery continued to increase through 12 months, with 44.4% RH patients recovering potency, versus 29% in the control group (p=0.002). IIEF-5 scores were significantly higher at both 3M (p<0.001) and 12M (p=0.001).
Subgroup analysis was repeated on young (<65) patients, with pre-operative IIEF-5>21, yielding similar results in both the linear and logistic regression models. In multivariate analysis, RH appeared to be the sole predictor of ultimate potency recovery at 12M.
Despite promising results by a single surgeon, Dr. Thomas Ahlering (PI), states that the ECB showed no statistically significant differences in recovery of sexual function in a multi-institutional, randomized control trial of five surgeons. Further, the primary endpoint of continence showed no differences between the RH and control groups. Instead, surgeon technique in minimizing injury trumps the possible benefits of RH.
Authors: Young Hwii Ko, Douglas Skarecky, Linda Huynh, Thomas Ahlering
Presented by: Young Hwii Ko (MD/PhD) of the University of California, Irvine
Written By: Linda Huynh (BS), an assistant research specialist from the University of California, Irvine, on behalf of UroToday.com
at the 2017 AUA Annual Meeting - May 12 - 16, 2017 – Boston, Massachusetts, USA